FOMX Insider Trading Activity and SEC Form 4 Filings
FOMX insider trading summary
No open-market insider purchases or sales of Foamix Pharmaceuticals Ltd. (FOMX) have been reported on SEC Form 4 in the past 12 months.
Latest FOMX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 10, 2019 | Ilan Hadar | CFO & Country Manager | Sell | $120K (34,392 @ $3.50) |
| Sep 9, 2019 | Ilan Hadar | CFO & Country Manager | Sell | $33K (9,420 @ $3.50) |
| Aug 26, 2019 | Anna Kazanchyan | Director | Sell | $23K (7,049 @ $3.27) |
| Jul 15, 2019 | Anna Kazanchyan | Director | Sell | $2K (808 @ $2.31) |
| Jul 1, 2019 | David Domzalski | CEO | Sell | $8K (3,355 @ $2.35) |
| Jul 1, 2019 | Mutya Harsch | CLO and General Counsel | Sell | $2K (639 @ $2.35) |
| Jul 1, 2019 | Iain Stuart | Chief Scientific Officer | Sell | $2K (951 @ $2.35) |
| May 20, 2019 | Anna Kazanchyan | Director | Sell | $28K (10,600 @ $2.61) |
| Apr 1, 2019 | Iain Stuart | Chief Scientific Officer | Sell | $6K (1,696 @ $3.75) |
| Apr 1, 2019 | Mutya Harsch | CLO and General Counsel | Sell | $9K (2,519 @ $3.75) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.